Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04685616 · ClinicalTrials.gov registry record · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
A Phase 3 study of Hodgkin Lymphoma, sponsored by University College, London.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,042
- Enrollment target
- 20
- Study locations
NCT04685616: Recruiting Phase 3 study of Hodgkin Lymphoma, sponsored by University College, London.
NCT04685616 is a Phase 3 study of Hodgkin Lymphoma that is actively recruiting participants, run by University College, London. The registered enrollment target is 1,042 participants, above the 151-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (590% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04685616, a Phase 3 study of Hodgkin Lymphoma, is actively recruiting participants, sponsored by University College, London.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,042 participants
- Enrollment target
- 20
- Study locations
Study Summary
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry. Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation. Patients will be followed up for a minimum of 5 years after treatment.
Primary Outcome
Time from randomisation to first date of progression or death
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Brentuximab vedotin
- DRUG Vinblastine
- RADIATION Involved site radiotherapy
- DRUG Bleomycin
Study Locations (20)
Other
- Royal Adelaide Hospital - Adelaide
- Box Hill Hospital - Box Hill
- Royal Brisbane and Women's Hospital - Brisbane
- Royal Darwin Hospital - Darwin
- Liverpool Hospital - Liverpool
- Sunshine Hospital (Western Health) - Melbourne
- Concord Repatriation General Hospital - Sydney
- St George Hospital - Sydney
- Universitair Ziekenhuis Antwerpen - Antwerp
- Ziekenhuis Netwerk Antwerpen - Antwerp
- UZ Leuven - Leuven
- CHU-UCL Namur - Namur
California
- Stanford University - (Stanford Cancer Institute) - Stanford
Florida
- University of Miami School of Medicine - Miami
New York
- Memorial Sloan Kettering Cancer Center - New York
New South Wales
- Royal North Shore Hospital - Saint Leonards
Queensland
- Townsville University Hospital - Townsville
West Flanders
- AZ Delta Campus Rumbeke - Roeselare
Nova Scotia
- QEII Health Sciences Centre - Halifax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,042 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2032-09 |
| Phase | Phase 3 |
What NCT04685616 shows while recruiting
NCT04685616 is an interventional study that assigns participants to a tested intervention. Its 1,042 participants enrollment target places it among the larger protocols in the corpus, above the 151-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (590% higher).
The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.
NCT04685616 names 20 study sites across 9 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04685616 about?
NCT04685616 is a clinical study titled "Brentuximab Vedotin in Early Stage Hodgkin Lymphoma". RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials G...
What is the current status of trial NCT04685616?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,042 participants. The study started on 2022-04-14. Estimated completion is 2032-09.
What conditions does trial NCT04685616 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma.
What interventions are being tested in trial NCT04685616?
The interventions under investigation include: Doxorubicin (DRUG), Brentuximab vedotin (DRUG), Vinblastine (DRUG), Involved site radiotherapy (RADIATION), Bleomycin (DRUG).
Who is sponsoring clinical trial NCT04685616?
This trial is sponsored by University College, London, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04685616 being conducted?
This trial has 20 study locations across California, Florida, New York, New South Wales, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04685616's enrollment target sits among peer trials
1,042 4th of 71 higher than 68 of 71 other Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RECRUITING · Phase 2
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
RECRUITING · Phase 2
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
- NCT06661720 · 1,040 participants · Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI